Research Peptide Supplier Scorecard for Canadian Buyers

Quick answer: what belongs in a research peptide supplier scorecard?#

A research peptide supplier scorecard is a structured way to compare Canadian research-material suppliers before a buyer relies on a catalogue page, certificate of analysis, or product claim. The scorecard should not ask, “Which site looks most polished?” It should ask whether the supplier can support a specific non-clinical research purchase with lot-level documentation, conservative claims, reachable support, and clear handling expectations.

A practical Canadian supplier scorecard should grade eight areas:

1. RUO boundary and claim discipline: whether the supplier avoids human dosing, disease-treatment claims, body-composition promises, cosmetic-result claims, testimonials, and protocol language.
2. COA quality: whether each material has a current, batch-specific certificate with lot number, test date, purity evidence, identity evidence, and lab attribution.
3. Lot traceability: whether the vial, order record, product page, and COA can be matched without detective work.
4. Analytical evidence: whether HPLC/UPLC purity and MS/LC-MS/MALDI identity are shown or available, not merely asserted.
5. Storage and vial controls: whether the supplier states storage temperature, light/moisture cautions, shipping expectations, fill amount, appearance, and retest or expiry guidance.
6. Support and document access: whether support can answer precise batch questions and provide missing records.
7. Catalogue clarity: whether product identity, salts/forms, blends, and related categories are described without conflating research mechanisms with outcomes.
8. Risk response: whether the buyer knows what to do when a supplier scores poorly.

This page gives a template, scoring scale, sample weights, red flags, and supplier questions. It is written for research-use-only procurement review. It is not medical advice, legal advice, dosing guidance, injection guidance, treatment guidance, cosmetic guidance, athletic-performance guidance, or a recommendation for personal use.

Downloadable-style template: the 100-point supplier scorecard#

Use this table as a worksheet. Assign a score in each row, keep notes, and attach supporting evidence such as COA screenshots, PDF file names, lot numbers, support emails, product-page dates, and storage instructions.

A supplier scoring 85-100 is relatively strong for documentation-first research procurement. A supplier scoring 70-84 may be usable only after missing records are requested and reviewed. A supplier scoring 50-69 should be treated as high-friction and high-uncertainty. A supplier scoring below 50 should not be relied on for serious research procurement without substantial remediation.

The score is not a certificate of safety. It is not a therapeutic endorsement. It is a way to avoid letting a clean website, a discount code, or one attractive purity number substitute for documented quality controls.

Why a scorecard beats a simple “best supplier” list#

Most “best peptide supplier” pages collapse different questions into one ranking. They mix price, shipping speed, catalogue size, user anecdotes, affiliate incentives, and vague trust language. That format is weak for research buyers because it hides the actual evidence.

A scorecard is better because it creates a visible audit trail. If Supplier A wins because it publishes current lot-specific COAs and answers documentation questions clearly, the reader can see that. If Supplier B loses points because it uses aggressive human-outcome language while hiding batch records, the reader can see that too. The scorecard turns trust into a set of inspectable claims.

This matters across compound categories. A buyer looking at broad research peptides may start with a category page for where to buy research peptides in Canada. A buyer comparing incretin-pathway research materials may look at Semaglutide, Tirzepatide, Retatrutide, or Cagrilintide. A buyer focused on recovery models may compare BPC-157, TB-500, and BPC-157 + TB-500 blend. A skin-research buyer may review GHK-Cu, LL-37, or KPV. The compound changes, but the evidence standard should not disappear.

A supplier scorecard also keeps compliance risk visible. If a page makes human-use claims, that should reduce the score even if the COA looks polished. Strong analytical documentation does not cancel weak claims.

Step 1: score the RUO boundary before the COA#

Start with the claims environment. A supplier that cannot keep its public copy inside research-use-only boundaries creates risk before the buyer even reaches the COA.

Award full points when the supplier:

• uses clear research-use-only language;
• avoids dosing, administration, injection, cycle, treatment, cure, diagnosis, prevention, athletic-performance, tanning, cosmetic-result, or body-transformation claims;
• avoids personal-use testimonials and before/after imagery;
• distinguishes research mechanisms from expected outcomes;
• avoids implying that a product is appropriate for humans because a study exists; and
• routes readers toward documentation and batch verification rather than protocols.

Deduct points when the site uses “for research only” language in one place but surrounds it with personal-use cues. A product page can say RUO and still be weak if it talks like a clinic, gym forum, or cosmetic-results page. A research buyer should not treat disclaimers as magic words. The whole page should respect the boundary.

This is especially important for categories with high consumer demand. Incretin-pathway compounds, skin peptides, growth-hormone secretagogues, recovery peptides, and cognitive peptides all attract non-research search traffic. A supplier that chases that traffic with human outcome claims is harder to trust as a research-material source.

For a deeper claims review, pair this scorecard with the research-use-only compliance checklist. That companion asset focuses on page language, disclosure structure, and red-flag wording.

Step 2: score the COA as a batch document, not a badge#

A certificate of analysis should connect a specific material to a specific batch. It should not function as decorative proof that “testing happened somewhere.”

Give the highest score when the COA includes:

• peptide name and, where useful, sequence, formula, salt/form, or molecular weight;
• lot or batch number that matches the vial/order record;
• test date and retest or expiry guidance;
• HPLC or UPLC purity result;
• chromatogram or peak table;
• mass-spectrometry identity evidence such as MS, LC-MS, or MALDI-TOF;
• expected and observed mass where available;
• fill amount or concentration/form description;
• storage conditions;
• lab, analyst, reviewer, or testing-source attribution; and
• document version or file date.

Deduct heavily when a supplier shows a single generic PDF for many batches, crops out identifiers, hides the test date, or claims very high purity without any trace detail. A purity number alone is not enough. HPLC purity and mass-spectrometry identity answer different questions. A strong score requires both composition evidence and identity evidence.

The companion peptide COA verification checklist gives a deeper row-by-row audit process. Use that checklist when a supplier is close enough to merit a full document review.

Step 3: match the lot before trusting the product page#

Lot traceability is the simplest place to catch weak suppliers. The buyer should be able to connect:

• product page;
• downloadable COA;
• vial label;
• packing slip or order record;
• support response if clarification is needed; and
• internal research inventory record.

If those identifiers do not match, the supplier may still be able to explain the mapping, but the score should drop until the explanation is documented. A representative COA is not the same as a current batch-specific COA. A document from a previous lot may show that the supplier has tested a material before, but it does not prove the current vial has the same profile.

This is not bureaucratic nitpicking. Research endpoints can be affected by model design, assay conditions, storage, operator technique, reagent quality, and material variation. Lot traceability helps keep those variables from being blurred together.

A high-scoring supplier makes traceability boring. The same identifier appears where it should. Support can answer quickly. The buyer does not need to infer that a PDF belongs to the current batch.

Step 4: score storage, vial condition, and shipping evidence#

Peptide procurement does not end at identity and purity. Materials can be affected by moisture, light, temperature excursions, repeated freeze-thaw events, oxidation, aggregation, vial seal problems, and unclear receipt conditions. A supplier that gives no handling guidance should lose points even if its COA looks acceptable.

Look for documentation on:

• lyophilized appearance;
• fill amount;
• vial and closure description;
• storage temperature before receipt;
• storage temperature after receipt;
• light and moisture cautions;
• shipping method and expected temperature exposure;
• retest or expiry guidance;
• what to do if a vial arrives warm, cracked, wet, unlabeled, or inconsistent; and
• whether cold-chain expectations differ by material.

A buyer reviewing SS-31, MOTS-c, NAD+, or Selank may care about different research models than a buyer reviewing GHK-Cu or BPC-157. But each case still needs storage and receipt documentation.

Use the peptide storage and vial inspection checklist after supplier selection, especially when a package arrives with ambiguous condition, damaged packaging, unclear labels, or missing records.

Step 5: test supplier support with precise questions#

Support quality is part of supplier quality. The fastest way to test it is to ask specific documentation questions before relying on a page.

Use questions like these:

1. Is the COA on this page batch-specific to the material currently shipping?
2. What lot number should appear on the vial and packing record?
3. Can you provide the HPLC chromatogram or peak table for this lot?
4. Can you provide MS, LC-MS, MALDI-TOF, or equivalent identity evidence?
5. What is the expected molecular mass and observed mass for this lot?
6. What storage conditions apply before and after receipt?
7. Is the material tested in-house, by a third-party analytical lab, or both?
8. Does the COA include fill amount, appearance, and test date?
9. If the vial label and PDF lot number differ, how are they mapped?
10. Can you confirm that the product is research-use-only and not intended for human or veterinary use?

High-scoring support answers the question asked, provides documents when appropriate, and does not drift into human-use advice. Low-scoring support sends generic assurances, refuses to clarify lot numbers, or starts discussing personal protocols. If a support channel gives dosing or administration guidance, that is a serious compliance red flag.

Step 6: compare category pages without letting one product carry the whole supplier#

One excellent product page does not prove the whole catalogue is well controlled. A scorecard should sample multiple pages across categories.

For a broad Canadian supplier review, inspect at least:

• one recovery-related material, such as BPC-157 or TB-500;
• one weight-management or incretin-pathway research material, such as Semaglutide or Tirzepatide;
• one skin or barrier research material, such as GHK-Cu or KPV;
• one cognitive or stress-modulation research material, such as Selank, Semax, or DSIP; and
• one mitochondrial or healthy-ageing research material, such as SS-31, MOTS-c, or Epitalon.

The goal is not to buy everything. The goal is to see whether the supplier’s documentation standard is systematic or isolated. A supplier that documents high-demand pages but neglects lower-volume materials may have uneven quality controls. A supplier that maintains clear COAs, conservative copy, and storage guidance across categories deserves a higher score.

Red flags that should cap the supplier score#

Some problems are serious enough that they should cap the total score even if other rows look strong.

Cap the score at 70 if:

• COAs are present but not batch-specific;
• support must manually explain every lot mapping;
• storage guidance is generic and incomplete;
• product pages are mostly compliant but contain occasional human-use wording; or
• analytical details are named but not visible.

Cap the score at 50 if:

• the supplier uses disease, treatment, dosing, cycle, or body-transformation language;
• COAs lack lot numbers or dates;
• support refuses to answer documentation questions;
• product pages present purity percentages without identity testing; or
• the catalogue contains many broken product links or unclear forms.

Cap the score at 30 if:

• the supplier gives human dosing or administration advice;
• documents appear copied, cropped, mismatched, or impossible to connect to current batches;
• the site uses fake-looking testimonials or before/after claims;
• product identity is unclear; or
• there is no credible route to obtain batch documentation.

These caps prevent a supplier from offsetting critical failures with cosmetic strengths. Fast shipping does not compensate for aggressive claims. A good price does not compensate for missing identity evidence. A polished product page does not compensate for no lot traceability.

How to use the scorecard in a procurement workflow#

For a practical workflow, use four passes.

Pass 1: screen the page. Read the supplier’s category and product pages. Remove any supplier that clearly pushes human use, dosing, disease claims, or transformation claims. Do not waste time scoring documents for a supplier whose public claims already fail the RUO boundary.

Pass 2: review batch evidence. Download or request the COA for the exact material and lot under consideration. Use the COA checklist to score analytical support. Confirm that purity, identity, lot number, test date, and storage guidance are present.

Pass 3: inspect logistics and receipt controls. Review shipping, storage, vial condition, and support language. Use the storage/vial checklist when the package arrives or when a supplier’s handling guidance is vague.

Pass 4: document the decision. Save the scorecard, COA, support emails, product-page URL, date reviewed, and notes. If the material is used in a research context, record the supplier score with the batch record so future interpretation does not depend on memory.

This workflow is intentionally conservative. It is easier to loosen standards later than to reconstruct documentation after a batch has been used, a page has changed, or a supplier has rotated stock.

Example scoring notes#

Here is a sample note style that keeps a review auditable without turning it into a novel:

The note does not claim the product is safe, effective, or suitable for human use. It documents why the supplier passed or failed a research procurement screen.

Adjust the weighting by research risk#

The 100-point version above is a strong default, but not every procurement question carries the same documentation burden. A buyer comparing a low-volume exploratory material should still care about COAs and RUO language, but a buyer planning a multi-batch study, a cross-site comparison, or a long storage interval should weight traceability and storage more heavily.

Use these adjustments when the research context is more demanding:

Do not lower the RUO boundary score for any scenario. Claim discipline is not optional because the material is familiar, popular, or widely discussed. If a supplier drifts into human-use language, the score should fall even when the analytical record is otherwise attractive.

For broad category reviews, keep the default weighting. For a specific study, add a short note explaining why any row was reweighted. That note makes the scorecard easier to interpret later when someone asks why two suppliers with similar COAs received different final scores.

How to compare two suppliers without overfitting the score#

A scorecard can create false precision if the buyer treats a one-point difference as meaningful. Supplier A scoring 82 and Supplier B scoring 84 are functionally similar unless the difference comes from a critical row. The better question is where the gap appears.

Use this comparison sequence:

1. Eliminate hard fails first. Remove any supplier with human-use claims, no batch-specific COAs, no lot traceability, or support that gives protocol-style advice.
2. Compare the weakest row, not only the total. A supplier with a high total but a poor storage score may be risky for temperature-sensitive materials.
3. Look for consistency across categories. A supplier that documents Semaglutide well but neglects Selank, GHK-Cu, or SS-31 may have uneven processes.
4. Request clarification before rejecting a near miss. Missing retest dates, unclear lab attribution, or limited method summaries may be fixable if support responds with current records.
5. Document why the winner won. The scorecard should say which evidence changed the decision, not just which supplier had the highest total.

This prevents the worksheet from becoming spreadsheet theatre. The goal is a defensible procurement decision, not a fake ranking system.

What to save with the completed scorecard#

A completed scorecard is most useful when it sits beside the evidence it summarizes. Save the review as a small packet:

• completed scorecard with date and reviewer;
• product page URL and capture date;
• COA PDF or screenshot with file name;
• lot number and vial label photo if available;
• support emails or chat transcript;
• storage/shipping instructions;
• receipt-condition notes;
• internal research inventory identifier; and
• decision note explaining whether the supplier was accepted, rejected, or held pending clarification.

This record matters because supplier pages change. COAs get replaced. Lots sell through. Support answers may differ between batches. If a research team needs to interpret results six months later, “the page looked fine” is not a useful audit trail. A saved scorecard packet gives the team a concrete record of what was known at the time.

For recurring purchases, repeat the scorecard at the lot level rather than assuming the supplier remains unchanged. A supplier can improve its documentation, weaken its copy, change fulfillment partners, rotate testing labs, or add new catalogue pages that do not meet the same standard. Supplier trust should be maintained, not inherited permanently.

Common scoring mistakes#

The most common mistake is giving too much credit for a clean website. Good design can improve usability, but it does not prove the material is documented. A supplier should earn points through records, traceability, and claim discipline.

Other mistakes include:

• treating a purity percentage as a complete COA;
• accepting a representative certificate as if it documents the current lot;
• ignoring storage language until after the package arrives;
• letting fast shipping offset weak analytical evidence;
• assuming a supplier is compliant because one page says research-use-only;
• scoring a product page without saving the version reviewed;
• using customer anecdotes as quality evidence;
• failing to ask support precise questions; and
• comparing prices before eliminating documentation failures.

A good scorecard makes those mistakes harder. It slows the buyer down at exactly the points where the market tries to speed them up.

One-page field checklist#

If the full worksheet is too much for a first pass, use this condensed field checklist. A supplier that cannot pass these questions should not move to price comparison.

This condensed version is useful for a first screen, but it should not replace the full scorecard for a supplier that will be used repeatedly, cited publicly, or compared across multiple peptide categories.

References and standards worth knowing#

The scorecard borrows from quality-system thinking without pretending that RUO peptide suppliers are equivalent to licensed drug manufacturers. The useful principles are traceability, risk management, analytical support, and reliable records.

Authoritative references that support this approach include:

• Health Canada Good manufacturing practices guide for drug products (GUI-0001), for quality-system and documentation principles in regulated drug contexts.
• Health Canada guidance on certificates of pharmaceutical products and GMP certificates (GUI-0024), for how regulated certificate language connects to site/product claims.
• Standards Council of Canada Good Laboratory Practices, for the role of quality systems in non-clinical data generation.
• OECD Principles on Good Laboratory Practice, for the quality and validity of non-clinical test data.
• ISO/IEC 17025 testing and calibration laboratories, for laboratory competence and reliable testing concepts.
• USP Reference Standards, for why characterized reference materials matter in analytical testing.

These references do not make a research peptide supplier “approved.” They simply give buyers a vocabulary for asking better questions about evidence, traceability, and documentation quality.

Supplier scorecard FAQ#

Bottom line#

A Canadian research peptide supplier should not win trust by having the loudest claims, the cleanest product photos, or the lowest price. It should win by making evidence easy to inspect.

Use this scorecard to compare suppliers on the things that matter for research procurement: RUO discipline, batch-specific COAs, lot traceability, analytical evidence, storage documentation, support quality, and practical Canadian buyer workflows. Then keep the completed scorecard with the COA and receipt records so the decision remains auditable later.

If a supplier cannot answer basic batch questions, do not let marketing language fill the gap. Move back to the evidence.